Pegascy

Pegascy specializes in repositioning oncology compounds that have been discontinued after Phase 1, by exploring their therapeutic potential in various indications. The company is currently developing istiratumab, a bispecific Igfr/Her3 antibody, in Phase 2 for Ewing's sarcoma and endometrial cancer. Following the success of PegaOne, which will be sold to Centessa in 2021, PEGASCY is preparing the launch of PegaTwo, targeting pediatric and female cancers.